PDCD1 and hereditary sensory and autonomic neuropathy: In clinical trials, the incidence of CIP is approximately 3% for monotherapy targeting either programmed cell death protein-1 (PD-1) or its ligand (PD-L1) and 7% for dual inhibition of PD-1 and cytotoxic T-lymphocyte-associated protein 4 [6-8].